Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.84 |
| ▸ | HTR2B | P41595 | 6/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.70 |
| ▸ | HTR2C | P28335 | 4/20 | 0.69 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.69 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25612586 | 0.91 | ADORA3 (1.00) | ADORA3ADORA1HTR2BADORA2ATMEM97 | |
| SCHEMBL19464901 | 0.84 | ADORA3 (0.87) | ADORA3ADORA1HTR2BADORA2ATMIGD3 | |
| SCHEMBL22933461 | 0.83 | ADORA3 (0.87) | ADORA3ADORA1HTR2BADORA2ATMIGD3 | |
| SCHEMBL3740327 | 0.82 | ADORA3 (1.00) | ADORA3ADORA1HTR2BADORA2ATMEM97 | |
| SCHEMBL1223325 | 0.82 | ADORA3 (1.00) | ADORA3ADORA1HTR2BADORA2ATMEM97 | |
| SCHEMBL19464931 | 0.80 | HTR2B (0.81) | ADORA3ADORA1HTR2BADORA2AHTR2C | |
| SCHEMBL19799152 | 0.80 | ADORA3 (0.80) | ADORA3ADORA1TMIGD3 | |
| SCHEMBL13276340 | 0.80 | ADORA3 (0.78) | ADORA3ADORA1HTR2BADORA2ATMEM97 | |
| SCHEMBL3727163 | 0.79 | ADORA3 (1.00) | ADORA3ADORA1TMIGD3HSP90B1 | |
| SCHEMBL25566677 | 0.79 | ADORA3 (1.00) | ADORA3ADORA1TMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885HTR2B 1044/4885 |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885HTR2B 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.